Han Kun, Foley & Lardner LLP and FTI Consulting hold seminar on recent legal and regulatory developments affecting the pharmaceutical industry
2015-11-11
The US Foreign Corrupt Practices Act (FCPA), and the PRC Anti-Trust Law and Intellectual Property Laws are among the most important laws with which Chinese businesses and legal practitioners must be familiar. The influence of the FCPA, which prohibits the bribing of foreign officials by US companies, stretches far beyond the borders of the United States. The China National Development and Reform Commission has also stated recently that the pharmaceutical industry and several other industries are to be targeted for enhanced anti-monopoly legal supervision and enforcement actions.
To address these widely concerning trends, on November 10, 2015, Han Kun, Foley & Lardner LLP and FTI Consulting held a seminar in Shanghai on recent legal and regulatory developments in the pharmaceutical industry, which specifically discussed the new China FDA approval processes, and current anti-bribery and FCPA practice issues.
During the seminar, a Foley & Lardner partner spoke on the interaction between the FCPA and anti-bribery laws, and a FTI Consulting senior managing director shared her personal experience on how to collect relevant information. Han Kun partners lectured on recent developments in anti-trust and intellectual property law in the pharmaceutical industry.
The seminar attracted legal and financial professionals from many international and domestic companies, and it turned out to be a great success.
